

302 – COST SETTLEMENT FOR CORONAVIRUS DISEASE OF 2019 VACCINE

EFFECTIVE DATES: 10/01/21, 03/01/22, [10/01/22¹](#)

APPROVAL DATES: 08/03/21, 01/24/22, [05/12/22²](#)

I. PURPOSE

This Policy applies to ACC, [ACC-RBHA³](#), ALTCS E/PD, DCS/CHP (CHP), DES/DDD (DDD), and RBHA Contractors. This Policy establishes requirements for cost settlement for Coronavirus Disease of 2019 (COVID-19) vaccine costs and Vaccine Administration Costs for October 1, 2021, to September 30, 202~~2~~³ (Contract Year Ending [CYE] 22 [and CYE 23 only⁴](#)). The Contractor is not contractually at risk for the cost of the vaccine or the Vaccine Administration Costs during CYE 22 [and CYE 23⁵](#). The anticipated costs have not been included in the CYE 22 [or CYE 23⁶](#) capitation rates; therefore, the Contractor will be provided payment via cost settlement as delineated in this Policy.

II. DEFINITIONS

For purposes of this Policy:

PREMIUM TAX The tax imposed pursuant to A.R.S. § 36-2905 and A.R.S. § 36-2944.01 for all payments made to the Contractor for the Contract year.

VACCINE ADMINISTRATION COST The cost of administering the vaccine. This is the cost of administering the COVID-19 vaccine using the CMS 1500 medical form, in the 837P format or through the point-of-sale (POS) system. **The COVID-19 vaccines are provided at no⁷ charge from the Federal government at the time of publication.**

[Additional definitions are located on the AHCCCS website at: AHCCCS Contract and Policy Dictionary.](#)

III. POLICY

A. GENERAL

This cost settlement shall relate solely to COVID-19 vaccine cost, if not provided by the Federal government at no charge, and Vaccine Administration Costs made by the Contractor for Title XIX

¹ [Date Policy is effective](#)

² [Date approved by APC](#)

³ [Revised to align with the Competitive Contract Expansion YH20-0002 to expand the provision of services for the awarded ACC Contractors.](#)

⁴ [Added the recon for CYE 23](#)

⁵ [Added the recon for CYE 23](#)

⁶ [Added for CYE 23](#)

⁷ [Corrected word](#)

and Title XXI members using the following list of approved Current Procedural Terminology (CPT) codes. State only members shall not be included in this reconciliation⁸:

- 0001A Pfizer-BioNTech COVID-19 Vaccine Administration First Dose
- 0002A Pfizer-BioNTech COVID-19 Vaccine Administration Second Dose
- 0003A Pfizer-BioNTech COVID-19 Vaccine Administration Third Dose
- 0004A Pfizer-BioNTech COVID-19 Vaccine Administration Booster
- 91300 Pfizer-BioNTech COVID-19 Vaccine
- 0011A Moderna COVID-19 Vaccine Administration First Dose
- 0012A Moderna COVID-19 Vaccine Administration Second Dose
- 0013A Moderna COVID-19 Vaccine Administration Third Dose
- 91301 Moderna COVID-19 Vaccine
- 0031A Janssen COVID-19 Vaccine Administration Single Dose
- 0034A Janssen COVID-19 Vaccine Administration Booster
- 91303 Janssen COVID-19 Vaccine
- 0021A* Astra Zeneca COVID-19 Vaccine Administration First Dose
- 0022A* Astra Zeneca COVID-19 Vaccine Administration Second Dose
- 91302* Astra Zeneca COVID-19 Vaccine
- 0041A* Novavax COVID-19 Vaccine Administration First Dose
- 0042A* Novavax COVID-19 Vaccine Administration Second Dose
- 91304* Novavax COVID-19 Vaccine
- 0051A Pfizer-BioNTech COVID-19 Vaccine -Tris-Sucrose Administration First Dose
- 0052A Pfizer-BioNTech COVID-19 Vaccine -Tris-Sucrose Administration Second Dose
- 0053A Pfizer-BioNTech COVID-19 Vaccine -Tris-Sucrose Administration Third Dose
- 0054A Pfizer-BioNTech COVID-19 Vaccine -Tris-Sucrose Administration Booster
- 91305 Pfizer-BioNTech COVID-19 Vaccine
- 0064A Moderna COVID-19 Vaccine Low Dose Booster
- 91306 Moderna COVID-19 Vaccine Low Dose
- 0071A Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose Administration First Dose
- 0072A Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose Administration Second Dose
- 0073A Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose Administration Third Dose
- 91307 Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose
- 0081A* Pfizer-BioNTech COVID-19 Pediatric Vaccine – Tris-Sucrose Administration First Dose
- 0082A* Pfizer-BioNTech COVID-19 Pediatric Vaccine – Tris-Sucrose Administration First Dose
- 91308* Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose
- M0201 Covid-19 Vaccine Home Administration

*Only to be included if granted full or emergency use approval by the Food and Drug Administration (FDA).

The following National Drug Codes (NDC) will be used for all vaccines provided in a Pharmacy by a pharmacist (Provider Type 03):

- 59267100001 Pfizer-BioNTech COVID-19 Vaccine Vial
- 59267100002 Pfizer-BioNTech COVID-19 Vaccine Carton
- 59267100003 Pfizer-BioNTech COVID-19 Vaccine Diluent
- 59267102501 Pfizer-BioNTech COVID-19 Vaccine Vial – Tris-Sucrose
- 59267105501 Pfizer-BioNTech COVID-19 Vaccine -Tris-Sucrose

⁸ Clarified State Only members are not included.

- 59267007801* Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose
- 59267007804* Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose
- 80777027310 Moderna COVID-19 Vaccine Vial
- 80777027399 Moderna COVID-19 Vaccine Carton
- 59676058005 Janssen COVID-19 Vaccine
- 59676058015 Janssen COVID-19 Vaccine Carton

*Only to be included if granted full or emergency use approval by the Food and Drug Administration (FDA).

B. AHCCCS RESPONSIBILITIES

1. AHCCCS/Division of Health Care Management (DHCM) shall pull fully adjudicated and approved encounters with only the CPT codes listed above. These pulls shall be made [for CYE 22](#)⁹ in March 2022, September 2022, and a final pull and settlement in September 2023. [For CYE 23 these pulls will be made in March 2023, September 2023, and September 2024](#)¹⁰. The cost settlement shall be conducted and payments, including Premium Tax, shall be made after each data pull. The cost settlement shall be conducted multiple times to identify and settle any vaccine costs and Vaccine Administration Costs not previously settled. All COVID-19 encounters adjudicated and approved after the September 2023 [and September 2024](#)¹¹ data pull, shall not be cost settled and shall not be included in any reconciliations or other cost settlements.
2. AHCCCS shall provide the Contractor the data used for the cost settlement and provide written notice of the deadlines for review and comment by the Contractor. Upon completion of the review period, AHCCCS shall evaluate Contractor comments and make any adjustments to the data as warranted. AHCCCS shall then process a payment based on the total amount paid for COVID-19 vaccinations less the previous payments made including premium tax. Refer to Attachment A for an example cost settlement.
3. AHCCCS shall reimburse the Contractor the lesser of the amount paid by the Contractor to the provider, or the Fee-For-Services (FFS) rates for the vaccine cost and Vaccine Administration Costs. All cost settlements to the Contractor shall include premium tax.

C. CONTRACTOR RESPONSIBILITIES

1. The Contractor shall submit encounters for COVID-19 vaccine costs and Vaccine Administration Costs and those encounters shall reach fully adjudicated and approved status by the date required by AHCCCS. AHCCCS shall only utilize fully adjudicated and approved encounters reported by the Contractor to determine the cost settlement.
2. The Contractor shall maintain financial statements that separately identify COVID-19 cost settlements as required by Contract and in the format specified in the AHCCCS Financial Reporting Guide.

⁹ [Added for clarity](#)

¹⁰ [Adding next year](#)

¹¹ [Adding date](#)